The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following: a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

A vector comprising a BPI3Vc backbone and at least one antigenic insert sequence from a pathogen other than BPI3V is provided. The vector is configured to provide protection against BPI3V as well as against the pathogen from which the insert sequence was obtained.

In one embodiment, the present disclosure provides an engineered cell having a first chimeric antigen receptor polypeptide including a first antigen recognition domain, a first signal peptide, a first hinge region, a first transmembrane domain, a first co-stimulatory domain, and a first signaling domain; and a second chimeric antigen receptor polypeptide including a second antigen recognition domain, a second signal peptide, a second hinge region, a second transmembrane domain, a second co-stimulatory domain, and a second signaling domain; wherein the first antigen recognition domain is different than the second antigen recognition domain.

The present invention includes a method of preparing apoptotic bodies from a tumour and immunogenic compositions thereof. The method of preparation comprises: obtaining human tumour cells from a subject, inducing apoptosis of the human tumour cells with a drug or a physical treatment, and collecting apoptotic bodies from the apoptotic human tumour cells by centrifugation. The method comprises two centrifugation steps, low-speed at 50 g for 5 minutes to pellet cells, followed by high-speed centrifugation of the obtained supernatant at 3,000 g for 8 minutes to pellet apoptotic bodies. The purity of the apoptotic bodies (also referred to as immunogenic Tumor Apoptotic Bodies (TABi)) was determined by FACS to be 82.22%.

Technologies for the prevention and/or treatment of nosocomial infections.

Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.

Provided herein, are methods of treating cancer in dogs using personalized cancer vaccines comprising peptides having frameshift mutations caused by errors in transcription and splicing of an mRNA.

The present invention relates generally to the identification of tumor specific neo open-reading-frame peptides (NOPs) and the uses of these NOPs to produce cancer vaccines and the like. More in particular the invention relates to identifying at least one neoantigen in a patient and based thereupon preparing a subject-specific immunogenic composition. With the present invention it becomes possible to provide off-the-shelf cancer vaccines and the like within a short period of time and for potentially 30% of the total population of patients suffering from cancer.

A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.

Technologies for the prevention and/or treatment of pneumococcal infections.